$247 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 71 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 47.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | New | SPDR SER TRcall | $22,392,000 | – | 200,000 | +100.0% | 9.08% | – |
| IMGN | Buy | IMMUNOGEN INC | $11,237,000 | +204.9% | 1,514,411 | +133.0% | 4.55% | +118.6% |
| BHVN | Buy | BIOHAVEN PHARMACTL HLDG CO L | $11,073,000 | +28.8% | 80,348 | +29.8% | 4.49% | -7.7% |
| ITCI | Buy | INTRA-CELLULAR THERAPIES INC | $10,206,000 | +168.7% | 195,000 | +91.4% | 4.14% | +92.6% |
| MRUS | Sell | MERUS N V | $10,182,000 | +33.8% | 320,174 | -7.5% | 4.13% | -4.1% |
| VCYT | Buy | VERACYTE INC | $9,120,000 | +9.4% | 221,362 | +23.3% | 3.70% | -21.6% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $8,912,000 | +9.7% | 60,757 | +32.3% | 3.61% | -21.4% |
| BLU | Buy | BELLUS HEALTH INC NEW | $8,855,000 | +295.1% | 1,100,000 | +201.4% | 3.59% | +183.3% |
| COGT | Buy | COGENT BIOSCIENCES INC | $7,301,000 | +28.1% | 850,935 | +25.5% | 2.96% | -8.2% |
| GLPG | New | GALAPAGOS NVspon adr | $7,106,000 | – | 128,901 | +100.0% | 2.88% | – |
| CERS | Buy | CERUS CORP | $7,101,000 | +88.3% | 1,042,722 | +68.4% | 2.88% | +35.0% |
| HZNP | Buy | HORIZON THERAPEUTICS PUB L | $6,649,000 | +15.7% | 61,700 | +17.6% | 2.70% | -17.1% |
| ITOS | Buy | ITEOS THERAPEUTICS INC | $6,426,000 | +103.5% | 138,006 | +18.0% | 2.60% | +45.9% |
| APEN | New | APOLLO ENDOSURGERY INC | $6,235,000 | – | 739,604 | +100.0% | 2.53% | – |
| RACB | Buy | RESEARCH ALLIANCE CORP II | $5,415,000 | +16.1% | 556,890 | +17.6% | 2.20% | -16.7% |
| IMTX | Sell | IMMATICS N.V | $5,257,000 | -7.6% | 391,155 | -10.7% | 2.13% | -33.8% |
| LHDX | Buy | LUCIRA HEALTH INC | $4,434,000 | +164.2% | 515,000 | +133.3% | 1.80% | +89.4% |
| SRRA | Buy | SIERRA ONCOLOGY INC | $4,175,000 | +16.5% | 192,045 | +17.5% | 1.69% | -16.5% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $4,162,000 | +33.4% | 286,226 | +65.1% | 1.69% | -4.4% |
| AMYT | Sell | AMRYT PHARMA PLCsponsored ads | $3,782,000 | -39.2% | 350,213 | -32.2% | 1.53% | -56.4% |
| CTIC | New | CTI BIOPHARMA CORP | $3,680,000 | – | 1,483,829 | +100.0% | 1.49% | – |
| LPTX | Buy | LEAP THERAPEUTICS INC | $3,284,000 | +32.1% | 1,013,664 | +63.5% | 1.33% | -5.3% |
| KRYS | New | KRYSTAL BIOTECH INC | $3,265,000 | – | 46,670 | +100.0% | 1.32% | – |
| MORF | Buy | MORPHIC HLDG INC | $3,195,000 | -2.2% | 67,440 | +16.9% | 1.30% | -29.9% |
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $3,178,000 | +205.9% | 111,860 | +126.5% | 1.29% | +119.4% |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $3,144,000 | -19.6% | 14,551 | -31.3% | 1.27% | -42.4% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $3,124,000 | +951.9% | 100,000 | +414.6% | 1.27% | +653.6% |
| HALO | Buy | HALOZYME THERAPEUTICS INC | $2,855,000 | +16.6% | 71,009 | +18.0% | 1.16% | -16.4% |
| INSM | Sell | INSMED INC | $2,741,000 | -43.0% | 100,621 | -42.4% | 1.11% | -59.1% |
| MCRB | Buy | SERES THERAPEUTICS INC | $2,671,000 | +39.6% | 320,602 | +16.7% | 1.08% | 0.0% |
| CYTK | Buy | CYTOKINETICS INC | $2,652,000 | +50.5% | 58,190 | +18.0% | 1.08% | +7.9% |
| OTIC | Buy | OTONOMY INC | $2,496,000 | +27.8% | 1,199,814 | +18.0% | 1.01% | -8.3% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $2,448,000 | +40.3% | 123,806 | +16.7% | 0.99% | +0.5% |
| VRAY | Buy | VIEWRAY INC | $2,357,000 | +76.7% | 427,847 | +131.2% | 0.96% | +26.7% |
| AUPH | New | AURINIA PHARMACEUTICALS INC | $2,287,000 | – | 100,000 | +100.0% | 0.93% | – |
| EYPT | Buy | EYEPOINT PHARMACEUTICALS INC | $2,226,000 | +65.3% | 181,886 | +40.7% | 0.90% | +18.4% |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $2,189,000 | – | 100,000 | +100.0% | 0.89% | – |
| STXS | Buy | STEREOTAXIS INC | $2,134,000 | +36.0% | 344,236 | +18.0% | 0.86% | -2.5% |
| JNCE | Buy | JOUNCE THERAPEUTICS INC | $2,053,000 | +32.5% | 245,829 | +17.9% | 0.83% | -5.0% |
| CYCC | Buy | CYCLACEL PHARMACEUTICALS INC | $1,783,000 | -12.9% | 458,466 | +18.0% | 0.72% | -37.6% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $1,744,000 | -15.5% | 45,132 | +18.0% | 0.71% | -39.4% |
| ASLN | New | ASLAN PHARMACEUTICALS LTDads | $1,678,000 | – | 1,498,192 | +100.0% | 0.68% | – |
| SGEN | Sell | SEAGEN INC | $1,677,000 | -15.9% | 10,848 | -7.7% | 0.68% | -39.7% |
| BBIO | New | BRIDGEBIO PHARMA INC | $1,668,000 | – | 100,000 | +100.0% | 0.68% | – |
| PSTX | New | POSEIDA THERAPEUTICS INC | $1,600,000 | – | 234,932 | +100.0% | 0.65% | – |
| DCPH | Buy | DECIPHERA PHARMACEUTICALS IN | $1,568,000 | +23.9% | 160,526 | +331.0% | 0.64% | -11.3% |
| BNTC | Buy | BENITEC BIOPHARMA INC | $1,539,000 | -13.4% | 587,499 | +18.0% | 0.62% | -37.9% |
| BIIB | Buy | BIOGEN INC | $1,378,000 | +11.0% | 5,744 | +30.9% | 0.56% | -20.5% |
| ELOX | Buy | ELOXX PHARMACEUTICALS INC | $1,363,000 | -33.6% | 1,930,092 | +53.2% | 0.55% | -52.5% |
| HLXA | Sell | HELIX ACQUISITION CORP | $1,304,000 | -41.4% | 131,823 | -41.1% | 0.53% | -58.0% |
| MSAC | Buy | MEDICUS SCIENCES ACQUISITION | $1,246,000 | +16.1% | 128,582 | +16.9% | 0.50% | -16.8% |
| PYPD | Buy | POLYPID LTD | $1,238,000 | -13.2% | 215,620 | +17.7% | 0.50% | -37.7% |
| DNAA | Buy | SOCIAL CAP SUVRETTA HLDS CRP | $1,230,000 | +16.6% | 123,862 | +16.9% | 0.50% | -16.4% |
| DNAC | Buy | SOCIAL CAP SUVRETTA HLD CRPI | $1,226,000 | +18.0% | 123,862 | +16.9% | 0.50% | -15.3% |
| DNAB | Buy | SOCIAL CAP SUVRETTA HLDS CRP | $1,225,000 | +17.0% | 123,862 | +16.9% | 0.50% | -16.2% |
| DNAD | Buy | SOCIAL CAP SUVRETTA HLDS CP | $1,216,000 | +16.9% | 123,862 | +16.9% | 0.49% | -16.2% |
| NXTC | Sell | NEXTCURE INC | $1,158,000 | -76.2% | 193,012 | -73.2% | 0.47% | -82.9% |
| PNT | Buy | POINT BIOPHARMA GLOBAL INC | $1,145,000 | +107.4% | 204,462 | +185.0% | 0.46% | +48.7% |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $1,098,000 | – | 5,000 | +100.0% | 0.44% | – |
| INBX | New | INHIBRX INC | $1,077,000 | – | 24,666 | +100.0% | 0.44% | – |
| CRIS | New | CURIS INCcall | $952,000 | – | 200,000 | +100.0% | 0.39% | – |
| KURA | Buy | KURA ONCOLOGY INC | $935,000 | -11.8% | 66,812 | +18.0% | 0.38% | -36.7% |
| IPHA | New | INNATE PHARMA S Asponsored ads | $839,000 | – | 184,046 | +100.0% | 0.34% | – |
| VTGN | Sell | VISTAGEN THERAPEUTICS INC | $827,000 | -57.3% | 424,181 | -40.1% | 0.34% | -69.4% |
| CGEN | Sell | COMPUGEN LTDord | $699,000 | -42.5% | 162,602 | -20.1% | 0.28% | -58.8% |
| EVGN | Buy | EVOGENE LTD | $481,000 | -26.7% | 293,057 | +18.0% | 0.20% | -47.4% |
| MREO | Sell | MEREO BIOPHARMA GROUP PLCads | $373,000 | -57.9% | 233,183 | -36.2% | 0.15% | -69.8% |
| CGEN | Sell | COMPUGEN LTDcall | $245,000 | -83.5% | 57,000 | -77.0% | 0.10% | -88.2% |
| CALA | Buy | CALITHERA BIOSCIENCES INC | $146,000 | -64.0% | 219,791 | +18.0% | 0.06% | -74.3% |
| RENOVACOR INC*w exp 99/99/999 | $60,000 | +42.9% | 104,828 | 0.0% | 0.02% | 0.0% | ||
| MSACW | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $36,000 | +2.9% | 49,990 | 0.0% | 0.02% | -25.0% | |
| CBIO | Exit | CATALYST BIOSCIENCES INC | $0 | – | -10,000 | -100.0% | -0.02% | – |
| Exit | ADAGIO THERAPEUTICS INC | $0 | – | -5,000 | -100.0% | -0.12% | – | |
| AFMD | Exit | AFFIMED N V | $0 | – | -47,182 | -100.0% | -0.16% | – |
| ARCT | Exit | ARCTURUS THERAPEUTICS HLDGS | $0 | – | -6,208 | -100.0% | -0.17% | – |
| RAPT | Exit | RAPT THERAPEUTICS INC | $0 | – | -11,796 | -100.0% | -0.21% | – |
| SURF | Exit | SURFACE ONCOLOGY INC | $0 | – | -50,000 | -100.0% | -0.21% | – |
| KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -10,000 | -100.0% | -0.22% | – |
| EVLO | Exit | EVELO BIOSCIENCES INCput | $0 | – | -61,700 | -100.0% | -0.24% | – |
| AYLA | Exit | AYALA PHARMACEUTICALS INC | $0 | – | -40,956 | -100.0% | -0.26% | – |
| CRIS | Exit | CURIS INC | $0 | – | -62,070 | -100.0% | -0.28% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -30,000 | -100.0% | -0.28% | – |
| CABA | Exit | CABALETTA BIO INC | $0 | – | -42,022 | -100.0% | -0.29% | – |
| GH | Exit | GUARDANT HEALTH INC | $0 | – | -4,218 | -100.0% | -0.30% | – |
| CLXPF | Exit | CYBIN INC | $0 | – | -250,000 | -100.0% | -0.31% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -31,040 | -100.0% | -0.35% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -4,950 | -100.0% | -0.38% | – |
| RNLX | Exit | RENALYTIX PLCads | $0 | – | -37,000 | -100.0% | -0.42% | – |
| ATHA | Exit | ATHIRA PHARMA INC | $0 | – | -106,388 | -100.0% | -0.56% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -18,581 | -100.0% | -0.62% | – |
| ADMS | Exit | ADAMAS PHARMACEUTICALS INC | $0 | – | -288,042 | -100.0% | -0.80% | – |
| ZNTL | Exit | ZENTALIS PHARMACEUTICALS INC | $0 | – | -23,855 | -100.0% | -0.90% | – |
| Exit | ERASCA INC | $0 | – | -93,122 | -100.0% | -1.12% | – | |
| CCXI | Exit | CHEMOCENTRYX INCput | $0 | – | -139,200 | -100.0% | -1.35% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -37,249 | -100.0% | -1.73% | – |
| FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -185,691 | -100.0% | -2.96% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
| 13F-HR | 2022-10-28 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.